



Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arab Emirates (UAE) market

OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd. (“Omnigene”), a Malta-based biotechnology company, providing advisory services within several therapeutic areas as cancer and neuroscience. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test, a CE-marked standardized gut microbiome test as a service to the UEA market.

Gut microbiome profiling is increasingly required in the field of precision medicine as a surrogate endpoint or exploratory biomarker in research. This is due both to the impact of the gut microbiome on our health and pharmaceuticals that can affect the microbiota composition itself. GA provides the first CE-marked and standardized microbiome test to profile and compare an imbalanced microbiota to healthy references. The standardized GA-map® Test is based on a pre-determined targets approach (PDT) and is establishing itself as a valuable tool in drug development, clinical research, and routine diagnostics.

The demand for the inclusion of gut microbiome assessments in clinics and academic research is rapidly increasing globally and the market in the UEA follows the same trend. Together with Omnigene, GA can now offer its CE-marked standardized gut microbiome test to the UAE market and meet the growing demand. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test as a service to the UAE market. The service offering will also target clinical research customers and medical customers.

Claudine Grech Spiteri, Executive Director, Omnigene, comments: *“We are committed to identifying and solving clinical needs to promote patient quality of life. By launching the microbiome profiling test from GA, we will strengthen our offerings to this rapidly growing precision medicine market. Our ambition is to expand and accelerate business in the UAE and we will soon enter the market with this clinical microbiome test powered by the GA-map® technology”*

Ronny Hermansen, CEO, Genetic Analysis, comments: *“GA is proud to have Omnigene Medical Technologies Ltd as a partner. The GA-map® platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation We believe microbiome*

testing will soon be a game-changer in medicine and the distribution agreement is well in line with our business strategy to expand to new markets.”

For further information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

Eilert Aamodt, Chief Financial Officer

E-mail: ea@genetic-analysis.com

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting-edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to helping unlock and restore the human microbiome through its state-of-the-art technology. GA employs 24 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com

About Omnigene Medical Technologies Ltd

Omnigene Medical Technologies Ltd. is a biotechnology start-up company, with the capacity of providing advisory services in genetic analysis, quality control of multiplex assays based on xMAP technology, and plans to set up an in vitro diagnostics manufacturing site providing kits for the diagnostic services.

Through collaborative efforts with international partners, the company enhanced its capacity to generate innovative products in the field of oncology, neuroscience, and emerging needs as evidenced by the research project on SARS-CoV-2 (COVID-19) immune response for vaccine surveillance.

For more information: www.genemt.com